• Chimeric Antigen Receptor Research
  • TCR Research
  • Oncolytic Virus Therapy Research
  • News
Creative Biolabs CAR-T Blog

Menu

Skip to content
  • Chimeric Antigen Receptor Research
  • TCR Research
  • Oncolytic Virus Therapy Research
  • News

Category Archives: Chimeric Antigen Receptor Research

02Jul/24

CAR-T Cells Targeting PSCA Show Promise in Treating Metastatic Castration-Resistant Prostate Cancer

July 2, 2024Cancer Immunotherapy, Chimeric Antigen Receptor Research, NewsCAR-T Cells, Prostate Cancer, PSCA-targeted CAR-T cellsbiocart

Treating prostate cancer with immunotherapy remains challenging. However, researchers at City of Hope have developed a chimeric antigen receptor (CAR) T cell (CAR-T) therapy, and the initial results of the first-in-human PhaseRead More…

20Jun/24

Advancements and Challenges in CAR-Macrophage Therapy: A New Frontier in Cancer Immunotherapy

June 20, 2024Cancer Immunotherapy, Chimeric Antigen Receptor ResearchCAR-macrophage therapybiocart

In recent years, Chimeric Antigen Receptor (CAR) technology has made significant progress in the treatment of hematologic malignancies, particularly in acute lymphoblastic leukemia (ALL), lymphoma, and plasma cell myeloma (PCM). However, theRead More…

27Mar/24

Overcoming Resistance: Enhancing CAR-T Therapy for AML with TP53 Mutations

March 27, 2024Chimeric Antigen Receptor Research, NewsCAR-T therapy, TP53biocart

Acute myeloid leukemia (AML) is an aggressive blood cancer caused by a plethora of genetic mutations acquired throughout one’s lifetime. One of these genes, the tumor suppressor gene TP53, plays a crucialRead More…

18Feb/24

Prospects of TCR-T Cell Therapy in Cancer Treatment

February 18, 2024Cancer Immunotherapy, Chimeric Antigen Receptor ResearchTCR-T cell therapy, TCR-T Therapybiocart

T-cell receptor-engineered T cells (TCR-T) represent a form of cellular immunotherapy and a subtype of adoptive cell transfer (ACT). It involves the identification and selection of TCR sequences capable of specifically bindingRead More…

26Jan/24

Positive Outcomes in Clinical Trial of Cord Blood-Derived CAR-NK Cell Therapy for B Cell Malignancies

January 26, 2024Chimeric Antigen Receptor Research, NewsB Cell Malignancies, CAR-NK, CD19biocart

In a recent study, researchers from the University of Texas MD Anderson Cancer Center in the United States reported favorable results from a Phase I/II clinical trial involving 37 patients with relapsedRead More…

06Dec/23

Enhancing CAR-T Cell Therapy: Modular Cytokine Receptors Boost Anti-Tumor Activity in Solid Tumors

December 6, 2023Cancer Immunotherapy, Chimeric Antigen Receptor ResearchCAR-T cell therapy, Solid Tumorsbiocart

The use of modified chimeric antigen receptor (CAR) T cells (CAR-T) in immunotherapy has significantly improved the survival rates of pediatric patients with relapsed leukemia. However, these therapies are not as effectiveRead More…

10Nov/23

CAR-T Cell Therapy May Lead to HHV-6 Virus Reactivation

November 10, 2023Chimeric Antigen Receptor Research, NewsCAR-T cell therapy, HHV-6biocart

In a recent study, researchers from Stanford University in the United States collected data from previous studies on CAR-T cell therapy to investigate the reactivation of human herpesvirus 6 (HHV-6) in patientsRead More…

05Oct/23

A Lego-Like Gene Editing Tool: ModPoKI, Paving the Way for Enhanced CAR-T Cell Therapy

October 5, 2023Chimeric Antigen Receptor Research, NewsCAR-T cell therapy, ModPoKIbiocart

In recent years, scientists have harnessed the power of gene editing technology to reprogram immune cells into therapies capable of targeting cancer. However, these immunotherapies are not universally effective across all patientsRead More…

02Sep/23

Single Dose of CAR-T Cells Holds Promise for Effective Ovarian Cancer Treatment

September 2, 2023Chimeric Antigen Receptor ResearchCAR-T cell therapy, Ovarian Cancerbiocart

In a recent study, researchers from the University of Illinois Urbana-Champaign in the United States have discovered that CAR-T cell immunotherapy could potentially be a highly effective treatment for solid tumors ifRead More…

14Aug/23

The Loss of Metabolic Adaptability Reveals a Key Mechanism of Tumor Resistance in CAR-NK Cells

August 14, 2023Cancer Immunotherapy, Chimeric Antigen Receptor ResearchCAR-NK, IL-15biocart

In a recent study conducted by researchers from institutions including the MD Anderson Cancer Center at the University of Texas, USA, it has been discovered that the loss of metabolic capacity inRead More…

Posts navigation

  • 1
  • 2
  • 3
  • …
  • 8
  • Next »

Categories

  • Cancer Immunotherapy
  • Chimeric Antigen Receptor Research
  • COVID-19
  • Events
  • HLA Typing
  • News
  • Oncolytic Virus Therapy Research
  • TCR Research

Recent Posts

  • CAR-T Cells Targeting PSCA Show Promise in Treating Metastatic Castration-Resistant Prostate Cancer
  • Advancements and Challenges in CAR-Macrophage Therapy: A New Frontier in Cancer Immunotherapy
  • NK Cell Surveillance Limits T Cell Responses: Implications for Cancer Immunotherapy
  • High-throughput Discovery of Tumor-Reactive T Cell Receptors: Advancing Personalized Cellular Immunotherapy
  • Overcoming Resistance: Enhancing CAR-T Therapy for AML with TP53 Mutations

Archives

Contact Us

USA - UK

Copyright © Creative Biolabs CAR-T Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Chimeric Antigen Receptor Research
  • TCR Research
  • Oncolytic Virus Therapy Research
  • News